Cytokinetics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
Rhea-AI Summary
Cytokinetics (Nasdaq: CYTK) announced participation in the 2026 RBC Capital Markets Global Healthcare Conference. Company management will join a fireside chat on May 19, 2026 at 3:35 PM ET in New York.
A live webcast and 90-day replay will be available via the Cytokinetics Investors & Media website.
Positive
- None.
Negative
- None.
News Market Reaction – CYTK
In the May 13 session, CYTK gained 3.22%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 11 | Clinical data update | Positive | -3.1% | New Phase 3 and real-world MYQORZO data at ESC Heart Failure 2026. |
| May 08 | Equity offering close | Negative | +3.5% | Closing of $805M common stock offering with full underwriter option exercise. |
| May 06 | Equity offering pricing | Negative | -0.7% | Pricing of upsized $700M common stock offering at $71 per share. |
| May 05 | Equity offering launch | Negative | -2.9% | Announcement of proposed ~$650M common stock offering with 15% option. |
| May 05 | Earnings and update | Positive | -2.9% | Q1 2026 results, MYQORZO launch revenue, EC approval and PDUFA date. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows negative reactions to both positive clinical/operational news and to dilutive equity offerings, with offerings sometimes seeing mixed price responses.
Over the past week, CYTK combined major financing and clinical milestones. On May 5, it reported Q1 2026 results with strong early MYQORZO launch revenue, EC approval and a Nov 14, 2026 PDUFA date, yet shares fell. Multiple equity offering steps on May 5–8 raised substantial capital and generally pressured the stock. On May 11, new Phase 3 and real‑world MYQORZO data also coincided with a decline. Today’s conference participation fits into a busy news flow following financings and clinical updates.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company management team will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19, 2026 at 3:35 PM Eastern Time in New York, NY.
Interested parties may access the live webcast of the fireside chat by visiting the Investors & Media section of the Cytokinetics website at https://ir.cytokinetics.com/. The webcast replays will be archived on the Cytokinetics website for 90 days following the conclusion of the event.
About Cytokinetics
Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics’ MYQORZO® (aficamten) is a cardiac myosin inhibitor approved in the U.S., Europe and China for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Following positive topline results in ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM (nHCM), the company is preparing to present the full results at an upcoming medical meeting and discuss them with the U.S. FDA and other regulatory authorities. Cytokinetics is also developing omecamtiv mecarbil, an investigational cardiac myosin activator for the potential treatment of patients with heart failure with severely reduced ejection fraction and ulacamten, an investigational cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction, while continuing pre-clinical research and development in muscle biology.
For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.
Disclaimer
Omecamtiv mecarbil and ulacamten are investigational medicines. They have not been approved nor determined to be safe or efficacious for any disease state or any indication by FDA or any other regulatory agency.
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act’s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics’ and its partners’ research and development activities of Cytokinetics’ product candidates. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics’ business outlines in Cytokinetics’ filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics’ actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
CYTOKINETICS® and the CYTOKINETICS C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.
MYQORZO® is a registered trademark of Cytokinetics in the U.S. and European Union.
Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757
